Effects of Kami Guibi-tang in patients with mild cognitive impairment: study protocol for a phase III, randomized, double-blind, and placebo-controlled trial

BACKGROUND: Amnestic mild cognitive impairment (aMCI) is often considered a precursor to Alzheimer’s disease (AD) and represents a key therapeutic target for early intervention of AD. However, no treatments have been approved for MCI at present. Our previous pilot study has shown that Kami Guibi-tan...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Hee-Yeon, Yim, Tae-Bin, Heo, Hye-Min, Jahng, Geon-Ho, Kwon, Seungwon, Cho, Seung-Yeon, Park, Seong-Uk, Jung, Woo-Sang, Moon, Sang-Kwan, Ko, Chang-Nam, Park, Jung-Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717542/
https://www.ncbi.nlm.nih.gov/pubmed/36461035
http://dx.doi.org/10.1186/s12906-022-03805-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717542/
https://www.ncbi.nlm.nih.gov/pubmed/36461035
http://dx.doi.org/10.1186/s12906-022-03805-9

Ejemplares similares